Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7198485 | 0.91 | CYP1A2 (0.39) | HSD17B10NPC1PKMRAB9ACYP1A2 | |
| SCHEMBL7194915 | 0.85 | MTNR1A (0.37) | HSD17B10NPC1PKMRAB9AMTNR1A | |
| SCHEMBL7195697 | 0.84 | NPC1 (0.44) | NPC1PKMRAB9ACYP1A2ALOX5 | |
| SCHEMBL7193913 | 0.83 | NPC1 (0.42) | HSD17B10NPC1PKMRAB9ACYP1A2 | |
| SCHEMBL7188224 | 0.83 | NPC1 (0.50) | NPC1PKMRAB9A | |
| SCHEMBL7198320 | 0.81 | CTNNB1 (0.44) | NPC1PKMRAB9A | |
| SCHEMBL7193634 | 0.78 | NFKB1 (0.35) | HSD17B10NPC1PKMRAB9ACYP19A1 | |
| SCHEMBL7196637 | 0.76 | CYP1A2 (0.54) | HSD17B10NPC1PKMRAB9ACYP1A2 | |
| SCHEMBL7188136 | 0.74 | NPC1 (0.39) | HSD17B10NPC1PKMRAB9AMTNR1A | |
| SCHEMBL7197963 | 0.72 | HSD17B10 (0.54) | HSD17B10NPC1PKMRAB9AMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030065039-A1 | Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-ones | STATENS SERUM INSTITUTE (DK) | 2003-04-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065039-A1 | Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-ones | AKR1C3, AKR1C1, AKR1A1 | HSD17B10 328/4885NPC1 3105/4885PKM 749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.